Emyria

Announcements

D4, 661 Newcastle Street
Leederville WA 6007

Montserrat

Emyria Limited

Dear current and prospective investors,

In response to Australia's mental health crisis, Emyria Ltd is dedicated to providing advanced therapies and compassionate care. We are focused on improving patient outcomes in neuroscience and mental health through our clinical service delivery, real-world data, and drug development initiatives.

Despite the challenging market conditions, our commitment to innovation and patient care remains steadfast. Our recent financial data reflects a decrease in revenue but a significant decrease in net loss, showcasing our continued efforts to optimize our operations.

We are actively working on developing proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5. Additionally, our partnerships and advanced data platform operated by Palantir enable us to collect robust real-world data to enhance our care models and support therapy and drug development initiatives.

We invite you to engage with us and ask any questions you may have regarding our recent initiatives and future plans. Our focus on addressing the growing global mental health challenge positions us uniquely in the market, with a clear growth strategy and major unmet needs to address.

Thank you for your continued support and interest in Emyria Ltd.

Best regards,
[Management Team at Emyria]

Australia's TGA to designate MDMA and psilocybin Schedule 8 “Controlled Medicines” from July 1st 2023, facilitating access to patients via appropriately qualified Authorised Prescribers [1]
Emyria uniquely positioned to advance and help commercialise MDMA-assisted therapies via:
<ul>
 <li class="typography-body-regular">Emyria’s established clinical &amp; data infrastructure - can support qualified Authorised Prescribers and therapists deliver MDMA-assisted therapy safely and at-scale</li>
 <li class="typography-body-regular">Real-World Data generation during treatment - can inform care model innovation, drug registration programs, and advance Emyria’s novel, advanced MDMA-inspired drug discovery program with partner the University of Western Australia</li>
</ul>
A short deck summarising Emyria’s updated strategy accompanies this announcement

Date	Headline
2 Nov 2026 1:21 PM	September 2026 Quarterly Investor Webinar Presentation
30 Oct 2026 8:52 AM	September 2026 Quarterly Investor Update Webinar Invitation
29 Oct 2026 9:50 AM	September 2026 Quarterly Activities Report and Appendix 4C
9 Oct 2026 11:40 AM	Annual Report
9 Oct 2026 11:37 AM	Appendix 4G and Corporate Governance Statement
9 Oct 2026 11:35 AM	Letter to Shareholders - Notice of Annual General Meeting
9 Oct 2026 11:34 AM	Notice of Annual General Meeting/Proxy Form
9 Oct 2026 11:31 AM	Retirement of Non-Executive Director
6 Oct 2026 9:36 AM	Webinar with Former Secretary of Veterans Affairs Dr Shulkin
6 Oct 2026 9:32 AM	Notification of cessation of securities - EMD

Annual reports

Investor presentations